Oral Micronized Progesterone (Prometrium) Dosing for Adults 30 to 49

This article covers oral micronized progesterone, sold under the brand name Prometrium (100 mg and 200 mg peanut-oil-based capsules) and available as generic equivalents. It is a bioidentical progesterone, meaning its molecular structure matches ovarian progesterone, and it is distinct from synthetic progestins such as medroxyprogesterone acetate and from vaginal micronized progesterone formulations, which behave differently pharmacokinetically.

Direct answer: The FDA-approved use of oral micronized progesterone in this context is endometrial protection in women taking estrogen who still have a uterus. The label supports two schedules: 200 mg orally at bedtime for 12 sequential days per 28-day cycle when paired with conjugated estrogens, or, in common practice extrapolated from that framework, 100 mg nightly on a continuous basis for women who are further past menopause and want to avoid a monthly withdrawal bleed. Everything beyond that core indication, heavy bleeding management, sleep support, premature ovarian insufficiency regimens, and fertility use, is either off-label or based on a different accountable body's guidance, not the Prometrium label itself.

What is FDA-approved versus extrapolated

It matters which claim rests on which authority, because the label, professional society guidance, and individual trials do not carry equal weight.

FDA-approved indication: Prometrium is approved for opposing unopposed estrogen in menopausal women with an intact uterus, to reduce the risk of endometrial hyperplasia. The label specifies 200 mg once daily at bedtime for 12 sequential days per 28-day cycle in combination with conjugated estrogens 0.625 mg (per the manufacturer's prescribing information).

Common continuous-combined practice: Using 100 mg nightly, every night, without a cyclic break is a widely used clinical approach for women who are further out from their final menstrual period and prefer not to have a withdrawal bleed. This pattern is consistent with the pharmacology of the drug but is not spelled out as a separate FDA-approved regimen in the same way the cyclic schedule is. Clinicians should treat it as standard-of-care extrapolation rather than a labeled indication, and confirm the specific regimen with the prescribing clinician.

Off-label or guideline-based uses: Cyclic progesterone for premature ovarian insufficiency, use for perimenopausal heavy menstrual bleeding, and use as a sleep aid independent of hormone therapy are supported to varying degrees by specialty society guidance and clinical trials, but they are not FDA-approved indications for this drug. Patients should understand that a prescription for these purposes is a clinical judgment call, not a label-directed use.

Not established: Precise numeric outcomes are sometimes quoted online for landmark trials in this space (the PEPI trial, the E3N cohort, the KEEPS trial, and smaller crossover studies of sleep and bleeding). Those trials are real and well known in the menopause literature, but exact effect sizes, confidence intervals, and enrollment figures should be verified against the original published trial report before being used for patient counseling. This draft intentionally avoids repeating specific numbers that could not be locally verified against the primary paper.

Cyclic versus continuous: how the choice is actually made

The choice between cyclic and continuous dosing is driven by menopausal status and bleeding tolerance, not by a fixed rule tied to age alone.

Cyclic dosing (200 mg at bedtime, 12 to 14 days per cycle) fits women who are perimenopausal or within roughly the first one to two years of their final menstrual period, who still have some endogenous cycling, or who want a predictable withdrawal bleed as a signal that the endometrium is shedding completely. This is the schedule the FDA label describes.

Continuous dosing (100 mg nightly, no break) fits women who are further past menopause and prefer to avoid monthly bleeding. Irregular spotting in the first three to six months of a continuous regimen is common and usually resolves on its own; if it does not resolve, or if bleeding starts after a period of no bleeding, that is a reason to be evaluated rather than to wait it out.

Neither schedule is "correct" in isolation. The right choice for an individual patient depends on where she is in the menopause transition, what estrogen dose and route she is using, her personal tolerance for breakthrough bleeding, and other health factors that a prescriber needs to review directly. This page cannot make that determination for an individual reader.

Off-label uses seen in adults 30 to 49

Adults in this age band include women with premature ovarian insufficiency, perimenopausal bleeding disorders, and active fertility goals, so the same drug gets used in several different ways.

Premature ovarian insufficiency (POI). Women diagnosed with POI before age 40 generally need hormone replacement until at least the average age of natural menopause. Specialty guidance on POI management (for example, ESHRE's guideline on premature ovarian insufficiency) supports cyclic progesterone paired with estradiol to mimic a physiologic cycle, partly because a preserved withdrawal-bleed pattern can help detect the intermittent spontaneous ovulation that occurs in a minority of POI cases. This is guideline-based practice, not an FDA-labeled indication for Prometrium specifically, and the exact regimen should be individualized.

Perimenopausal heavy or irregular bleeding. Cyclic oral micronized progesterone is used off-label to regularize erratic perimenopausal cycles and reduce heavy bleeding. Trial evidence supporting this use exists, but a precise magnitude of blood-loss reduction should not be quoted without verifying the source trial directly; treat any specific milliliter figure you encounter elsewhere with caution until confirmed.

Fertility and luteal phase support. Oral micronized progesterone is used in some fertility protocols for luteal phase support, but vaginal micronized progesterone is more commonly preferred in IVF cycles because it reaches higher local uterine tissue concentrations relative to serum levels. A crossover pharmacokinetic study comparing oral dydrogesterone with vaginal micronized progesterone for luteal support found meaningful pharmacokinetic and endometrial differences between routes, which is one reason route selection is not interchangeable in fertility care (Pharmacokinetics and endometrium study, 2024). Anyone using progesterone while trying to conceive should coordinate the specific regimen with a reproductive endocrinologist rather than following a generic HRT dosing schedule.

Sleep support. Oral progesterone is metabolized in the liver to allopregnanolone, a neurosteroid that acts on GABA-A receptors and produces sedation. This is why the drug is dosed at bedtime, and why some perimenopausal women report better sleep on it. Using it specifically as a sleep aid independent of an estrogen or endometrial-protection indication is an off-label use and should be discussed as such with a prescriber.

A framework for the clinician conversation and follow-up

Because so much of this drug's real-world use sits outside the narrow FDA label, the more useful tool for a patient is a structured way to talk to a prescriber and know when a symptom needs escalation rather than reassurance. This checklist is a discussion aid, not a substitute for individualized care.

Before starting: questions to raise with a prescriber

• Is this being prescribed for FDA-labeled endometrial protection, or for an off-label reason (POI, bleeding control, sleep, fertility)? Ask directly, because the monitoring plan differs.
• Which regimen is intended: cyclic 200 mg for 12 to 14 days, or continuous 100 mg nightly, and why that one for me specifically?
• Do I have a peanut allergy, active liver disease, or a history of hormone-sensitive cancer that changes this recommendation?
• Am I on a strong CYP3A4 inhibitor (such as certain antifungals or protease inhibitors) or inducer (such as rifampin or some anticonvulsants), which can respectively increase sedation or reduce effectiveness?

First 3 months: what to track and report

• Bleeding pattern: timing, heaviness, and whether it matches what was predicted for the chosen regimen.
• Sleep and daytime grogginess, since bedtime dosing is meant to convert sedation into a benefit rather than a burden.
• Mood changes. A minority of women experience irritability or low mood on oral progesterone, thought to relate to individual sensitivity to allopregnanolone at the GABA-A receptor.
• Tolerability overall, including bloating and breast tenderness, which are more common with cyclic 200 mg dosing than continuous 100 mg dosing and typically ease over two to three cycles.

Stop-and-call conditions (do not wait for the next scheduled visit)

• New bleeding after a period of no bleeding on a continuous regimen, or bleeding that is markedly heavier or longer than expected on a cyclic regimen.
• Signs of an allergic reaction, particularly in anyone with a peanut allergy taking a peanut-oil-based brand capsule.
• New or worsening depressive symptoms, especially if there is any thought of self-harm; this warrants urgent evaluation, not a wait-and-see approach.
• Signs of liver dysfunction (jaundice, right upper quadrant pain, unusual fatigue) in anyone with pre-existing liver disease.
• Any bleeding evaluated as unexpected in a postmenopausal woman should prompt transvaginal ultrasound assessment of endometrial thickness, and biopsy if the endometrial stripe is thickened, per gynecologic oncology and endometrial cancer screening guidance. A 2025 study evaluating postmenopausal bleeding on estrogen plus body-identical progesterone regimens reinforces that unscheduled bleeding needs structural endometrial evaluation rather than reassurance alone (Endometrial thickness and pathology study, 2025); the specific thresholds used in that population should be confirmed with a treating clinician rather than applied as a fixed rule here.

Annual reassessment

• Is continued therapy still needed, and does the original indication still apply?
• Has the risk-benefit balance changed (new cardiovascular risk factors, new personal or family cancer history)?
• Is the dosing route still appropriate, or would a vaginal or transdermal alternative better serve current goals (for example, after a new diagnosis of liver disease)?

Practical administration

Take the capsule whole, at bedtime, with a small amount of dietary fat. The FDA label documents a substantial increase in peak blood concentration when the capsule is taken with food compared with fasting, so a light snack containing some fat improves and stabilizes absorption (per the manufacturer's prescribing information). Do not crush or open the capsule, since micronization is designed to control the dissolution rate.

If a dose is missed the same evening, take it as soon as remembered. If an entire day is missed, skip that dose and resume the next scheduled evening rather than doubling up. Missing multiple consecutive doses during a cyclic course can trigger unexpected breakthrough bleeding, which should be reported rather than managed independently.

Prometrium brand capsules are formulated in peanut oil and are contraindicated for patients with a confirmed peanut allergy. Compounded micronized progesterone or a non-peanut-oil generic formulation, where available, is the alternative to discuss with a prescriber.

Why serum progesterone levels are not used to monitor this drug

A meaningful practical point that is often missed: oral micronized progesterone produces highly variable serum concentrations with rapid peaks and troughs after each dose, so a random blood level drawn after oral dosing does not reliably reflect tissue exposure or treatment adequacy. Monitoring instead relies on clinical endpoints, bleeding pattern, symptom control, and endometrial thickness on ultrasound when bleeding is unexpected, rather than a target progesterone level. Anyone told to get a routine progesterone blood test purely to check whether an oral dose is "working" should ask the ordering clinician what specific question that test is meant to answer.

Special populations and interactions

Liver disease. Oral micronized progesterone undergoes extensive first-pass hepatic metabolism, and significant liver impairment is a reason to avoid the oral route. Vaginal progesterone, which largely bypasses first-pass metabolism, is often considered a safer alternative in this situation, and this decision should be made with the prescribing clinician rather than self-directed.

Renal impairment. Standard HRT doses are not generally reported to require adjustment for mild to moderate renal impairment, though individualized judgment still applies.

Body weight. Endometrial protection at standard doses has not been shown to require weight-based adjustment, though higher hepatic blood flow in some patients may intensify the sedative effect.

Drug interactions. Progesterone is metabolized primarily through CYP3A4. Strong CYP3A4 inhibitors (certain antifungals, some antibiotics, some antivirals) can increase progesterone exposure and sedation; strong inducers (rifampin, carbamazepine, phenytoin, among others) can reduce effectiveness and increase breakthrough bleeding risk. No formal dose-adjustment study defines an exact compensating dose change, so clinical monitoring for side effects or bleeding guides management rather than a fixed protocol.

What is established, what is plausible, and what is not established

Established: Oral micronized progesterone is FDA-approved for endometrial protection against unopposed estrogen, dosed at 200 mg nightly for 12 sequential days per cycle per the label. It causes dose-dependent sedation through hepatic conversion to allopregnanolone, which is why bedtime dosing is standard. Serum levels after oral dosing are not a reliable monitoring tool. Peanut allergy is a contraindication to the brand capsule specifically.

Plausible but requiring individualized confirmation: That micronized progesterone has a more favorable cardiovascular and breast-tissue safety profile than synthetic progestins is a widely discussed hypothesis in the menopause literature and reflected in professional society commentary, but head-to-head long-term randomized comparisons in the 30-to-49 population specifically are limited, and exact risk figures circulating for landmark trials should be checked against the original publication before being used in patient counseling.

Not established on this page's evidence: A specific milliliter reduction in menstrual blood loss, a specific percentage of mood-symptom incidence, and precise relative-risk figures from cohort studies are not verified here to the level of precision sometimes quoted elsewhere, and should not be treated as confirmed numbers until checked against the primary paper.

When to seek care sooner rather than later

Unexpected or heavy vaginal bleeding, signs of an allergic reaction, new depressive symptoms with any thought of self-harm, or signs of liver dysfunction all warrant contacting a clinician promptly rather than waiting for a scheduled follow-up. This is general safety guidance, not a substitute for an individualized plan from the prescribing clinician.